SCHEMBL21987104

SCHEMBL21987104

CC(C)c1cnc(-c2ccccc2)nc1Nc1ccnc2[nH]cc(N3CCCCC3)c12

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 19/20 0.45
ROCK1 Q13464 19/20 0.45
CDC42BPB Q9Y5S2 19/20 0.45
CDC42BPA Q5VT25 5/20 0.45
CDC7 O00311 1/20 0.39
ROS1 P08922 1/20 0.39
KIT P10721 1/20 0.39
MARK3 P27448 1/20 0.39
FLT3 P36888 1/20 0.39
CDK8 P49336 1/20 0.39
MAP2K1 Q02750 1/20 0.39
MAP3K10 Q02779 1/20 0.39
STK3 Q13188 1/20 0.39
MELK Q14680 1/20 0.39
LRRK2 Q5S007 1/20 0.39
MARK4 Q96L34 1/20 0.39
CAMKK2 Q96RR4 1/20 0.39
SIK2 Q9H0K1 1/20 0.39
CAMK2A Q9UQM7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21190173 0.92 ROCK1 (0.43) ROCK2ROCK1CDC42BPBCDC42BPA
SCHEMBL21190142 0.91 ROCK2 (0.42) ROCK2ROCK1CDC42BPBCDC42BPA
SCHEMBL21189975 0.89 ROCK2 (0.40) ROCK2ROCK1CDC42BPBCDC42BPA
SCHEMBL21190153 0.84 ROCK2 (0.41) ROCK2ROCK1CDC42BPBCDC42BPA
SCHEMBL21177471 0.84 ROCK1 (0.39) ROCK2ROCK1CDC42BPBCDC42BPA
SCHEMBL21190038 0.83 LRRK2 (0.43) ROCK2ROCK1CDC42BPBSTK3LRRK2
SCHEMBL21190143 0.82 ROCK2 (0.36) ROCK2ROCK1CDC42BPBCDC42BPACDC7
SCHEMBL21189980 0.82 ROCK2 (0.44) ROCK2ROCK1CDC42BPBCDC42BPALRRK2
SCHEMBL21177228 0.81 ROCK2 (0.44) ROCK2ROCK1CDC42BPBCDC42BPA
Hydrochloric Acid SCHEMBL21177443 0.81 ROCK2 (0.44) ROCK2ROCK1CDC42BPBCDC42BPA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200171030-A1 DUAL INHIBITORS OF ALK5 AND P38A MAP KINASE INTEGRAL BIOSCIENCES PRIVATE LTD (IN) 2020-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200171030-A1 DUAL INHIBITORS OF ALK5 AND P38A MAP KINASE MAP2K2, MAP2K5, MAP2K1 ROCK2 160/4885ROCK1 159/4885CDC42BPB 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.